EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation

Linhai Zhu, Yanye Wang, Xuhua Huang, Xide Liu, Bo Ye, Yi He, Haojie Yu, Wang Lv, Luming Wang, Jian Hu iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.6942 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Linhai Zhu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Cyclooctanes, Lignans, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Zhejiang Province Lung Tumor Diagnosis and Treatment Technology Research Supported by the Center, Zhejiang Provincial Traditional Chinese Medicine, The Zhejiang Medicine and Health General Research Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The purpose of this study is to explore the biological mechanism of Schizandrin A (SchA) inducing non‐small cell lung cancer (NSCLC) apoptosis.

Methods

The reverse molecular docking tool “Swiss Target Prediction” was used to predict the targets of SchA. Protein–protein interaction analysis was performed on potential targets using the String database. Functional enrichment analyses of potential targets were performed with Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. The conformation of SchA binding to target was simulated by chemical‐protein interactomics and molecular docking. The effect of SchA on the expression and phosphorylation level of EGFR was detected by Western blot. Lipofectamine 3000 and EGFR plasmids were used to overexpress EGFR. Apoptosis was tested with Annexin V‐FITC and propidium iodide staining, and cell cycle was detected by propidium iodide staining.

Results

The “Swiss Target Prediction” database predicted 112 and 111 targets based on the 2D and 3D structures of SchA, respectively, of which kinases accounted for the most, accounting for 24%. Protein interaction network analyses showed that molecular targets such as ERBB family and SRC were at the center of the network. Functional enrichment analyses indicated that ERBB‐related signaling pathways were enriched. Compound‐protein interactomics and molecular docking revealed that SchA could bind to the ATP‐active pocket of the EGFR tyrosine kinase domain. Laboratory results showed that SchA inhibited the phosphorylation of EGFR. Insulin could counteract the cytotoxic effect of SchA. EGFR overexpression and excess EGF or IGF‐1 had limited impacts on the cytotoxicity of SchA.

Conclusions

Network pharmacology analyses suggested that ERBB family members may be the targets of SchA. SchA can inhibit NSCLC at least in part by inhibiting EGFR phosphorylation, and activating the EGFR bypass can neutralize the cytotoxicity of SchA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungCyclooctanesLignansLung NeoplasmsPolycyclic CompoundsHumansApoptosisCell Line, TumorErbB ReceptorsMolecular Docking Simulation

Stichwörter der Autor:innen

EGFRSchizandrin Aapoptosiscell cyclenon-small cell lung cancer

Substanzen

CyclooctanesErbB ReceptorsLignansPolycyclic Compoundsschizandrin A

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
  • Department of Arthropathy, Zhejiang University of Traditional Chinese Medicine Affiliated Integrated Chinese and Western Medicine Hospital, Hangzhou, China.
  • Department of Thoracic Surgery, Hangzhou Red Cross Hospital, Hangzhou, China.
  • State Key Laboratory of Subtropical Silviculture, Zhejiang A&F University, Hangzhou, China.
  • State Key Laboratory of Chemical Engineering, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, China.
  • Key Laboratory of Clinical Evaluation Technology for Medical device of Zhejiang Province, Hangzhou, China.

ORCID-Profile: Jian Hu

Förderung

  • The Zhejiang Province Lung Tumor Diagnosis and Treatment Technology Research Supported by the Center
  • Zhejiang Provincial Traditional Chinese Medicine
  • The Zhejiang Medicine and Health General Research Program
  • The Zhejiang Province Major Science and Technology Special Program Project
  • The National Key Research and Development Program

Zitieren

APA

Zhu, L., Wang, Y., Huang, X., Liu, X., Ye, B., He, Y., Yu, H., Lv, W., Wang, L., & Hu, J. (2024). Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation. Cancer Medicine. https://doi.org/10.1002/cam4.6942

Vancouver

Zhu L, Wang Y, Huang X, Liu X, Ye B, He Y, et al. Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation. Cancer Medicine. 2024. doi:10.1002/cam4.6942

BibTeX
@article{Zhu2024,
  author = {Zhu, Linhai and Wang, Yanye and Huang, Xuhua and Liu, Xide and Ye, Bo and He, Yi and Yu, Haojie and Lv, Wang and Wang, Luming and Hu, Jian},
  title = {Schizandrin A induces non‐small cell lung cancer apoptosis by suppressing the epidermal growth factor receptor activation},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.6942}
}
Kostenlos starten →